ClinicalTrials.gg
Active, not recruitingNCT00581906Updated Mar 4, 2026

Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors

An observational study in Head and Neck Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
272
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center — 6 open to participants now, 11 under way, none of them phase 3. Head and Neck Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
3rd of 14
272 · median 152
Started
2006
with 3 others
Observational
14 of 52
4 open now
Primary completion
2027-02
later than 1 of 10 live
Registered
15th of 52
by date

Among the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 3rd largest by enrollment of the 14 observational ones that give a count, is one of 4 that started in 2006, is one of 14 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 15th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

6 of the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Magnetic resonance imaging (MRI) is a diagnostic study that makes pictures of organs of the body using magnetic field and radio frequency pulses that can not be felt. Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) uses faster imaging and contrast material (a substance used to make specific organs, blood vessels, or tumors easier to see) that is given by vein. Diffusion weighted magnetic resonance imaging (DW-MRI) allows to measure the motion of water around the cells in the tumor. Proton magnetic resonance spectroscopy (MRS) obtains chemical information from the tumor. During MRS, signals are detected from the chemicals (spectroscopy) naturally present in your tumor using radio waves. DCE-MRI, DW-MRI and MRS give extra information which is not available with the regular MRI. The regular MRI only shows pictures of the tumor while the DCE-MRI also gives information about the blood vessels of the tumor. DW-MRI provides information related to the state of the tumor tissue with regards to the quality or condition of cells present in it and MRS gives information about the chemical makeup of the tumor.

The purpose of this study is to see whether DCE-MRI, DW-MRI and MRS done before treatment can predict which patients will do well with either surgery or chemo-radiation therapy. This study will also see if DCE-MRI, DW-MRI and MRS done early in treatment can tell if the therapy is working.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • Head and Neck Cancer
  • Head Cancer
  • Neck Cancer
  • Dynamic Contrast Enhanced MRI
  • Magnetic Resonance Spectroscopy (MRS)
  • Diffusion Weighted MRI (DW-MRI)
  • 06-007
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Potential research subjects will be identified by a member of the patient's treatment team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer Center (MSKCC).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven diagnosis of head and neck cancer or patients with tumors strongly suspicious for head and neck cancer due to clinical features or FNA (fine needle aspiration) cytology assessment.
  • Will undergo surgery or chemo-radiation treatment
  • Patients must be 18 years or older and have the ability to give

Exclusion criteria

Exclusion Criteria:

  • Claustrophobia
  • Known reaction to Gd-DTPA
  • Pre-operative radiation to primary tumor site
  • to MRI

    1. Pacemaker
    2. Aneurysmal clips
    3. Metal implants in field of view
    4. Pregnant or nursing women
    5. Age and mental status wherein he/she is unable to cooperate for MRI study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
272 participants (actual)

Groups and cohorts

  • pts undergoing surgery or chemo-radiation treatment

    Radiation: DCE-MRI, DW-MRI and MRS

Interventions

  • RadiationDCE-MRI, DW-MRI and MRS

    Pts undergo DCE-MRI, DW-MRI or 1\^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) \& group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI \&/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite \& will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st \& 2nd weeks of treatment \& the 2nd intra-treatment DCE-MRI is recommended between the 3rd \& 4th weeks of treatment.

06

What researchers measure

Primary outcomes

  1. Identify a priori prognostic markers for head and neck cancer patients using DCE-MRI, DW-MRI and 1H-MRS data, which may help in stratifying patients into "good risk" and "poor risk" categories to improve outcome and quality of life.

    Time frame: 5 years

Secondary outcomes

  1. To determine if the a-priori DCE-MRI, DW-MRI and 1H-MRS results provide independent markers of tumor response and/or long term disease-free survival compared to clinical prognosticators.

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Feb 2027 and a completion of Feb 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Dec 28, 2007
Start
Feb 2006
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00581906
Responsible party
Sponsor
First posted
Dec 28, 2007
Start date
Feb 2006
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Amita Dave, PhD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion